Alluvi Tirzepatide 40mg Pen is a laboratory-grade peptide formulation developed for scientific investigation into dual incretin receptor activity and metabolic pathway interaction.
Containing 40mg Tirzepatide, this precision peptide pen is commonly examined in laboratory environments for its interaction with GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptor pathways.
Research involving Alluvi Tirzepatide 40mg Pen frequently focuses on metabolic signalling, endocrine pathway behaviour, receptor-binding dynamics, peptide pharmacology, and energy homeostasis modelling under controlled laboratory conditions.
The precision multi-dose pen system supports consistent measurement throughout structured laboratory protocols, allowing accurate evaluation of peptide stability, receptor interaction, and dose-response characteristics.
This formulation is intended strictly for laboratory and scientific research use.
Key Features
- Premium 40mg Tirzepatide peptide formulation
- Precision multi-dose peptide pen
- Dual GLP-1 and GIP receptor agonist
- Examined for metabolic and endocrine pathway research
- Laboratory-grade manufacturing standards
- Designed for controlled scientific research applications
Research Applications
Tirzepatide research commonly focuses on:
- GLP-1 receptor pathway studies
- GIP receptor signalling research
- Metabolic pathway investigation
- Endocrine signalling analysis
- Receptor-binding modelling
- Energy homeostasis research
- Peptide-response evaluation
- Metabolic regulation studies
Why Choose Alluvi Healthcare?
- Trusted manufacturer of premium peptide formulations
- Precision-engineered peptide pen technology
- High-purity laboratory-grade peptides
- Consistent manufacturing standards
- Designed specifically for scientific investigation
- Widely utilised within controlled research environments
How to Use (Research Reference Only)
This product is intended strictly for laboratory and scientific research conducted under controlled experimental protocols.
Not intended for human consumption.
Package Contents
- 1 × Alluvi Tirzepatide 40mg Pen
- 12 × Disposable needles
- Instruction booklet
Research Disclaimer
For laboratory and scientific research use only.
Not intended for human consumption, therapeutic use, veterinary application, or medical treatment.
About Tirzepatide
Tirzepatide is a dual incretin receptor agonist commonly examined within laboratory research for its interaction with GLP-1 and GIP receptor pathways. Current scientific investigations focus on metabolic signalling, endocrine regulation, receptor-binding behaviour, peptide pharmacology, and energy homeostasis under controlled laboratory conditions.
Reviews
There are no reviews yet.